{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:15:17Z","timestamp":1788560117516,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"DOI":"10.1038\/s41416-026-03607-7","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:40:10Z","timestamp":1788558010000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PD-L1 expression and survival in unresectable\/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1"],"prefix":"10.1038","author":[{"given":"Hidekazu","family":"Hirano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0692-8419","authenticated-orcid":false,"given":"Yasuhide","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4529-9045","authenticated-orcid":false,"given":"Kengo","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4215-4385","authenticated-orcid":false,"given":"Nobuyoshi","family":"Hiraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0884-8981","authenticated-orcid":false,"given":"Shigeki","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizutomo","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Iwasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kanato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomu","family":"Machida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3280-4850","authenticated-orcid":false,"given":"Hisato","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Takahari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyasu","family":"Ojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9923-5309","authenticated-orcid":false,"given":"Shigenori","family":"Kadowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1438-707X","authenticated-orcid":false,"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2883-0132","authenticated-orcid":false,"given":"Yukinori","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaki","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"3607_CR1","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"3607_CR2","doi-asserted-by":"publisher","first-page":"156","DOI":"10.35772\/ghm.2019.01025","volume":"2","author":"Y Yamada","year":"2020","unstructured":"Yamada Y. Present status and perspective of chemotherapy for patients with unresectable advanced or metastatic gastric cancer in Japan. Glob Health Med. 2020;2:156\u201363.","journal-title":"Glob Health Med"},{"key":"3607_CR3","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1005\u201320.","journal-title":"Ann Oncol"},{"key":"3607_CR4","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S2468-1253(19)30083-4","volume":"4","author":"Y Yamada","year":"2019","unstructured":"Yamada Y, Boku N, Mizusawa J, Iwasa S, Kadowaki S, Nakayama N, et al. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2019;4:501\u201310.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3607_CR5","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh D-Y, Ya\u00f1ez P, Bai Y, Ryu M-H, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1181\u201395.","journal-title":"Lancet Oncol"},{"key":"3607_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340.","journal-title":"Lancet"},{"key":"3607_CR7","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:234\u201347.","journal-title":"Lancet Oncol"},{"key":"3607_CR8","doi-asserted-by":"publisher","first-page":"e078876","DOI":"10.1136\/bmj-2023-078876","volume":"385","author":"MZ Qiu","year":"2024","unstructured":"Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ. 2024;385:e078876.","journal-title":"BMJ"},{"key":"3607_CR9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.6004\/jnccn.2025.0022","volume":"23","author":"JA Ajani","year":"2025","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Corvera CU, Das P, Enzinger PC, et al. Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025;23:169\u201391.","journal-title":"J Natl Compr Canc Netw"},{"key":"3607_CR10","doi-asserted-by":"crossref","unstructured":"Formica V, Morelli C, Fornaro L, Riondino S, Rofei M, Fontana E, et al. PD-L1 thresholds predict efficacy of immune checkpoint inhibition in first-line treatment of advanced gastroesophageal adenocarcinoma. A systematic review and meta-analysis of seven phase III randomized trials. ESMO Open. 2024;9:103967.","DOI":"10.1016\/j.esmoop.2024.103967"},{"key":"3607_CR11","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/JTO.0000000000000414","volume":"10","author":"H Ishii","year":"2015","unstructured":"Ishii H, Azuma K, Kawahara A, Yamada K, Imamura Y, Tokito T, et al. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. J Thorac Oncol. 2015;10:426\u201330.","journal-title":"J Thorac Oncol"},{"key":"3607_CR12","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.2217\/fon-2021-1184","volume":"18","author":"R Woodford","year":"2022","unstructured":"Woodford R, Zhou D, Lord SJ, Marschner I, Cooper WA, Lewis CR, et al. PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer. Future Oncol. 2022;18:1793\u20139.","journal-title":"Future Oncol"},{"key":"3607_CR13","doi-asserted-by":"crossref","unstructured":"Akimoto E, Kuwata T, Shitara K, Kawazoe A, Sakamoto N, Ishii G, et al. Impact of programmed death-ligand 1 expression on mismatch repair deficiency and Epstein\u2013Barr virus status on survival outcomes in patients with stage II\/III gastric cancer after surgery. Ann Surg Oncol. 2023;30:5227\u201336.","DOI":"10.1245\/s10434-023-13266-0"},{"key":"3607_CR14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10120-016-0631-3","volume":"20","author":"A Kawazoe","year":"2017","unstructured":"Kawazoe A, Kuwata T, Kuboki Y, Shitara K, Nagatsuma AK, Aizawa M, et al. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. Gastric Cancer. 2017;20:407\u201315.","journal-title":"Gastric Cancer"},{"key":"3607_CR15","doi-asserted-by":"publisher","first-page":"24269","DOI":"10.18632\/oncotarget.8169","volume":"7","author":"C B\u00f6ger","year":"2016","unstructured":"B\u00f6ger C, Behrens HM, Mathiak M, Kr\u00fcger S, Kalthoff H, R\u00f6cken C. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. Oncotarget. 2016;7:24269\u201383.","journal-title":"Oncotarget"},{"key":"3607_CR16","doi-asserted-by":"publisher","first-page":"e0182692","DOI":"10.1371\/journal.pone.0182692","volume":"12","author":"L Gu","year":"2017","unstructured":"Gu L, Chen M, Guo D, Zhu H, Zhang W, Pan J, et al. PD-L1 and gastric cancer prognosis: a systematic review and meta-analysis. PLoS ONE. 2017;12:e0182692.","journal-title":"PLoS ONE"},{"key":"3607_CR17","doi-asserted-by":"publisher","first-page":"661","DOI":"10.4143\/crt.2019.718","volume":"52","author":"Y Park","year":"2020","unstructured":"Park Y, Koh J, Na HY, Kwak Y, Lee KW, Ahn SH, et al. PD-L1 testing in gastric cancer by the combined positive score of the 22C3 PharmDx and SP263 assay with clinically relevant cut-offs. Cancer Res Treat. 2020;52:661\u201370.","journal-title":"Cancer Res Treat"},{"key":"3607_CR18","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s10147-020-01684-z","volume":"25","author":"S Iwasa","year":"2020","unstructured":"Iwasa S, Kudo T, Takahari D, Hara H, Kato K, Satoh T. Practical guidance for the evaluation of disease progression and the decision to change treatment in patients with advanced gastric cancer receiving chemotherapy. Int J Clin Oncol. 2020;25:1223\u201332.","journal-title":"Int J Clin Oncol"},{"key":"3607_CR19","doi-asserted-by":"publisher","first-page":"148","DOI":"10.21037\/jgo.2017.01.10","volume":"8","author":"F Petrelli","year":"2017","unstructured":"Petrelli F, Berenato R, Turati L, Mennitto A, Steccanella F, Caporale M, et al. Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis. J Gastrointest Oncol. 2017;8:148\u201363.","journal-title":"J Gastrointest Oncol"},{"key":"3607_CR20","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.21037\/jgo-21-505","volume":"12","author":"Y Narita","year":"2021","unstructured":"Narita Y, Sasaki E, Masuishi T, Taniguchi H, Kadowaki S, Ito S, et al. PD-L1 immunohistochemistry comparison of 22C3 and 28-8 assays for gastric cancer. J Gastrointest Oncol. 2021;12:2696\u2013705.","journal-title":"J Gastrointest Oncol"},{"key":"3607_CR21","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s10120-022-01301-0","volume":"25","author":"J Yeong","year":"2022","unstructured":"Yeong J, Lum HYJ, Teo CB, Tan BKJ, Chan YH, Tay RYK, et al. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Gastric Cancer. 2022;25:741\u201350.","journal-title":"Gastric Cancer"},{"key":"3607_CR22","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1200\/JCO.2025.43.4_suppl.364","volume":"43","author":"M Onishi","year":"2025","unstructured":"Onishi M, Ogura N, Inamoto R, Kito Y, Nagashima K, Takahashi N, et al. Correlation between PD-L1 CPS and clinical outcomes in patients treated with first-line nivolumab plus chemotherapy for advanced gastric or gastroesophageal junction cancer: a multi-center retrospective study in Japan. J Clin Oncol. 2025;43:364.","journal-title":"J Clin Oncol."},{"key":"3607_CR23","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1093\/annonc\/mdy264","volume":"29","author":"YJ Bang","year":"2018","unstructured":"Bang YJ, Ruiz EY, Van Cutsem E, Lee KW, Wyrwicz L, Schenker M, et al. Phase III, randomised trial of avelumab versus physician\u2019s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol. 2018;29:2052\u201360.","journal-title":"Ann Oncol"},{"key":"3607_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2023.100154","volume":"36","author":"ME Robert","year":"2023","unstructured":"Robert ME, R\u00fcschoff J, Jasani B, Graham RP, Badve SS, Rodriguez-Justo M, et al. High interobserver variability among pathologists using combined positive score to evaluate pd-l1 expression in gastric, gastroesophageal junction, and esophageal adenocarcinoma. Mod Pathol. 2023;36:100154.","journal-title":"Mod Pathol"},{"key":"3607_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-73013-3","volume":"10","author":"Y Qin","year":"2020","unstructured":"Qin Y, Jiang L, Yu M, Li Y, Zhou X, Wang Y, et al. PD-L1 expression is a promising predictor of survival in patients with advanced lung adenocarcinoma undergoing pemetrexed maintenance therapy. Sci Rep. 2020;10:16150.","journal-title":"Sci Rep"},{"key":"3607_CR26","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793\u2013800.","journal-title":"Nat Med"},{"key":"3607_CR27","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA. 2002;99:12293\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3607_CR28","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/2326-6066.CIR-16-0391","volume":"5","author":"T Noguchi","year":"2017","unstructured":"Noguchi T, Ward JP, Gubin MM, Arthur CD, Lee SH, Hundal J, et al. Temporally distinct PD-L1 expression by tumor and host cells contributes to immune escape. Cancer Immunol Res. 2017;5:106\u201317.","journal-title":"Cancer Immunol Res"},{"key":"3607_CR29","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1172\/JCI96061","volume":"128","author":"H Tang","year":"2018","unstructured":"Tang H, Liang Y, Anders RA, Taube JM, Qiu X, Mulgaonkar A, et al. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J Clin Investig. 2018;128:580\u20138.","journal-title":"J Clin Investig"},{"key":"3607_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14572","volume":"8","author":"J Lau","year":"2017","unstructured":"Lau J, Cheung J, Navarro A, Lianoglou S, Haley B, Totpal K, et al. Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. Nat Commun. 2017;8:14572.","journal-title":"Nat Commun"},{"key":"3607_CR31","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1084\/jem.20160801","volume":"214","author":"VR Juneja","year":"2017","unstructured":"Juneja VR, McGuire KA, Manguso RT, LaFleur MW, Collins N, Haining WN, et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017;214:895\u2013904.","journal-title":"J Exp Med"},{"key":"3607_CR32","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393:1948\u201357.","journal-title":"Lancet"},{"key":"3607_CR33","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2503701","volume":"393","author":"YY Janjigian","year":"2025","unstructured":"Janjigian YY, Al-Batran S-E, Wainberg ZA, Muro K, Molena D, Cutsem EV, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med. 2025;393:217\u201330.","journal-title":"N Engl J Med"},{"key":"3607_CR34","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S1470-2045(25)00130-5","volume":"26","author":"A Zaanan","year":"2025","unstructured":"Zaanan A, Bouch\u00e9 O, De La Fouchardi\u00e8re C, Le Malicot K, Pernot S, Louvet C, et al. TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2025;26:732\u201344.","journal-title":"Lancet Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03607-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03607-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03607-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:40:12Z","timestamp":1788558012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03607-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":34,"alternative-id":["3607"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03607-7","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"14 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HH has received honoraria from Bristol-Myers Squibb, Ono Pharmaceutical, Novartis, Daiichi-Sankyo, and Taiho Pharmaceutical and grants from PPD, Daiichi-Sankyo, Nippon Boehringer Ingelheim, ALX Oncology, BeiGene, Novartis, Amgen, Bristol-Myers Squibb, Seagen, and Taiho Pharmaceutical. KN has received consulting fee from SENJU Pharmaceutical Co., Ltd. and Kowa Company, Ltd.; KN\u2019s institution has received a consulting fee from Eli Lilly. NT has received honoraria from Bristol-Myers Squibb, Ono Pharmaceutical, Taiho Pharmaceutical, and AstraZeneca. SK has received grants from Ono Pharmaceutical, MSD, Nobelpharma, Janssen Pharmaceutical K.K., Eli Lilly, Chugai, Daiichi-Sankyo, AstraZeneca, Abbvie, Kyowa Kirin, Astellas, Novartis, and Bayer and honoraria from Ono Pharmaceutical, Taiho Pharmaceutical, MSD, Daiichi-Sankyo, Merck KGaA, BMS, Eli Lilly, Chugai, Bayer, Eisai, Novartis, and Astellas. HK has received consulting fees from Daiichi-Sankyo, Astellas Pharma, AbbVie, and Chugai Pharmaceutical; honoraria from Bristol-Myers Squibb, Bayer Yakuhin, Eli Lilly Japan, MSD, Ono Pharmaceutical, Chugai Pharmaceutical, Daiichi Sankyo, Merck Biopharma, Takeda Pharmaceutical, Takata Pharmaceutical, Taiho Pharmaceutical, Otsuka Pharmaceutical, Nippon Kayaku, GlaxoSmithKline, Amgen, Novartis, Astellas Pharma, BeOne Medicine Japan, AstraZeneca, and Miyarisan Pharmaceutical; and grants or contracts from Hitachi, Bristol-Myers Squibb, Ono Pharmaceutical, MSD, Ascent Development Services, ICON Clinical Research, Kobayashi Pharmaceutical, Nippon Boehringer Ingelheim, Medpace Japan, Amgen, and Astellas. M.T. has received honoraria from Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd, Ono Pharmaceutical Co., Ltd, Bristol-Myers Squibb Japan K.K., Yakult Honsha Co., Ltd., AstraZeneca Co. Ltd, Eli Lilly Japan K.K., Astellas Pharm. Inc., Daiichi Sankyo Ltd., Johnson and Johnson K.K., Medtronic Japan Co., Ltd, Intuitive Japan Inc., and Olympus Co., Ltd. The other authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Written informed consent was obtained from patients who could be contacted for follow-up. For patients who had died or were lost to follow-up, an opt-out procedure was adopted, whereby information about the study was publicly disclosed and an opportunity to refuse participation was provided in accordance with Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects. The protocol of this translational study was approved by the institutional review board of the Japan Institute for Health Security National Center and each participating hospital and complied according to the criteria of REMARK (reporting recommendations for tumour marker prognostic studies).","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}